This editorial interprets an integrative review that identified metabolic pathways linking ketogenic interventions to post‑traumatic stress disorder (PTSD). Preclinical rodent work suggests potential symptom modulation, while human data are limited to small feasibility studies without robust efficacy signals.
Study and findings
The authors performed an integrative review, searching multiple bibliographic databases and trial registries for any preclinical, clinical, observational, mechanistic or review article that examined ketogenic therapy (including classical ketogenic diet, very‑low‑carbohydrate ketogenic diets, exogenous ketone salts, esters or medium‑chain triglycerides) in relation to PTSD. Sixteen records met inclusion criteria: nine human studies, four animal experiments and three narrative reviews. The review maps several metabolic and signaling cascades—mitochondrial bioenergetics, inflammation, oxidative stress, HPA‑axis modulation and neurotransmitter balance—through which elevated circulating ketone bodies could theoretically counteract PTSD‑related pathophysiology. Rodent experiments (n = 93) reported reductions in fear‑conditioning responses and normalization of stress‑induced glucose dysregulation after ketogenic diet or ketone supplementation. Human investigations (total n = 724) were limited to feasibility, safety and pilot efficacy assessments; no large randomized trial was identified. Reported safety outcomes did not reveal PTSD‑specific adverse signals, and adherence rates were comparable to other dietary interventions.
Clinical interpretation
The mechanistic rationale presented aligns with known metabolic disturbances in PTSD, such as impaired mitochondrial function and heightened inflammation. Preclinical data therefore support the hypothesis that ketogenic therapy could modulate these pathways and attenuate stress‑related behaviors. However, the human evidence base consists only of small, uncontrolled or early‑phase trials that primarily address feasibility rather than therapeutic benefit. Consequently, while the review suggests that ketogenic interventions are biologically plausible and appear safe in PTSD cohorts, it does not provide evidence that they improve core PTSD symptoms or functional outcomes. Clinicians should regard ketogenic therapy as an experimental adjunct pending rigorous efficacy data.
Limitations and open questions
The principal limitation is the paucity of high‑quality clinical data; no adequately powered randomized controlled trial has examined ketogenic therapy for PTSD, and existing human studies lack control groups or blinding. The animal literature, although promising, cannot be directly extrapolated to patients because dosing regimens, diet composition and stress models differ from clinical reality. Safety reporting is limited to short‑term observations, leaving long‑term metabolic effects in PTSD populations uncertain. Future research must address these gaps with well‑designed, double‑blind, placebo‑controlled trials that specify diet macronutrient ratios, ketone target levels, and standardized outcome measures for PTSD symptom clusters.
Source
Engelhardt R, Ogedengbe JO, Millet MS, Ayad MEG, Schalinski I, Von Oertzen T, et al. Ketogenic therapy as a potential novel treatment approach for PTSD: an integrative review and proposed mechanistic model. Front Psychiatry. 2026;17:1854499. doi: 10.3389/fpsyt.2026.1854499. PMID: 42780737.